The co-delivery of a drug and a target gene has become a primary strategy in cancer therapy. Based on our previous study, a synthesized star-shaped co-polymer consisting of β-cyclodextrin (CD) and a poly(L-lysine) dendron (PLLD) was used to co-deliver docetaxel (DOC) and matrix metalloproteinase 9 (MMP-9) small interfering RNA, via CD-PLLD/DOC/MMP-9 complexes, into mice implanted with HNE-1 human nasopharyngeal carcinoma (NPC) tumor cells in vivo. Unlike the commonly used amphiphilic co-polymer micelles, the obtained CD derivative may be used directly for a combined delivery of nucleic acid and hydrophobic DOC without a complicated micellization process. In vivo assays demonstrated that CD-PLLD/DOC/MMP-9 inhibited HNE-1 tumor growth and decreased proliferating cell nuclear antigen expression levels, indicating a potential strategy for NPC therapy. In addition, the distribution of DOC and MMP-9 was investigated; CD-PLLD/DOC/MMP-9 complexes were phagocytized in reticuloendothelial systems, including the liver and spleen, which requires further study. Furthermore, the complexes did not cross the blood-brain barrier due to their large molecular size, suggesting they may be relatively safe. Additionally, the complexes mediated increased DOC concentrations with prolonged blood circulation and EGFP expression in HNE-1 tumors. These results suggest the future potential application of CD-PLLD/DOC/MMP-9 for NPC therapy.
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common types of malignant tumor in southern China (1) . Currently, a combination of radiotherapy and chemotherapy is the primary clinical treatment for NPC. However, the average five-year survival rate of patients with advanced NPC remains low due to tumor metastasis and multi-drug resistance (2) .
A recent study demonstrated that combining chemotherapy with gene therapy may mediate synergistic actions, enhance treatment effects and inhibit the development of drug resistance (3) . Furthermore, He et al (4) developed a drug and gene co-delivery system, using zinc ions (Zn 2+ ) as the connecting point. The obtained coordination liposome mediated the cellular uptake of cisplatin and small interfering (si)RNA, and enabled efficient endosomal escape in cisplatin-resistant ovarian cancer cells. Li et al (5) used poly (carboxybetaine) to conjugate camptothecin, and assembled cationic liposomes to form a drug and gene dual-carrier, which demonstrated a synergistic tumor suppression effect in tumor-bearing mice in vivo. Chang et al (6) assembled drug and gene co-delivering liposomes from amphiphilic pillar [5] arene capped with ferrocenium, which exhibited redox sensitivity and effective drug/siRNA co-delivery.
Previous studies have incorporated hydrophobic anticancer drugs into the hydrophobic cores of these carriers, and bound plasmid DNA or siRNA to cationic hydrophilic shells. However, the self-assembly processes involved in the preparation of micelles are typically difficult to control, and therefore stable and uniform complexes are difficult to obtain. Furthermore, micelles are not stable in blood circulation in vivo, and their disassembly may result in drug emission (7) (8) (9) . A recent study synthesized a star-shaped cyclodextrin (CD) derivative, consisting of a CD core and poly(L-lysine) dendron (PLLD) arms (CD-PLLD) (10) . The CD core may interact with hydrophobic drug models, thus avoiding the complicated micellization process.
For gene delivery, hyperbranched or dendrimer cationic polymers, including poly (amidoamine)s, have been widely used and have demonstrated efficiency due to their topologic structure (11, 12) . Of these, PLLD and its derivatives are of interest due to their well-defined architecture, good biocompatibility, low cytotoxicity, high transfection efficiency and biodegradability. Previous studies have investigated their synthesis and potential applications in drug or gene delivery (13) (14) (15) . The synthesized CD-PLLD demonstrated stability and good gene delivery ability in our previous study (10) , and was used to co-deliver docetaxel (DOC) and a matrix metalloproteinase 9 (MMP-9) siRNA plasmid for NPC therapy (16) . The present study investigated the distributions of MMP-9 and DOC in vivo, and the potential of using the CD-PLLD/DOC/MMP-9 complex for NPC treatment. In addition, it was demonstrated in vitro that CD-PLLD may co-deliver DOC and MMP-9 effectively into HNE-1 NPC cells, and that these cells underwent apoptosis, therefore suggesting its potential application in drug and gene co-delivery.
Materials and methods
Materials. CD-PLLD/DOC/MMP-9 complexes were synthesized according to our previous study (the loading amount of DOC was 13.20 µg/mg) (16) . DOC was purchased from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany) and used without further purification. The most efficient interference MMP-9 siRNA plasmid vector expressing enhanced green fluorescent protein (EGFP), selected following screening (16) , was purchased from Invitrogen; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The optimum siRNA sequences targeting MMP-9 were as follows: Forward, 5'-TGC TGA AAC CGA GTT GGA ACC ACG ACG TTT TGG CCA CTG ACT GAC GTC GTG GTC AAC TCG GTTT-3' and reverse, 5'-CCT GAA ACC GAG TTG ACC ACG ACG TCA GTC AGT GG C CAA AAC GTC GTG GTT CCA ACT CGG TTTC-3'. Tert-butyl methyl ether and acetonitrile were of analytical grade and used without further purification. HNE-1 human NPC cells were provided by Southern Medical University (Guangzhou, China). A total of 50 female specific pathogen-free BALB/c nude mice (age, 4-5 weeks; weight, 17-20 g) maintained at a specific pathogen free facility with a constant humidity (60%) and temperature (28˚C) at 12/12 h light/dark cycle with free access to food and water were obtained from the Center for Laboratory Animal Sciences, Southern Medical University. Ethical approval was obtained from The Institutional Administration Panel for Laboratory Animal Care of Southern Medical University. The university guidelines for care and use of laboratory animals were strictly followed.
In vivo metabolism assay in nude mice. Nude mice implanted with HNE-1 tumors were used as the animal model for in vivo analyses. HNE-1 cells (1x10 7 cells in 200 µl PBS) were injected subcutaneously into the right axillary flank of female BALB/c nude mice. Once the tumors had grown to a maximum of 1 cm in diameter, the mice were sacrificed by cervical dislocation, and the HNE-1 tumors were removed and sectioned into 2x2x2 mm small pieces in aseptic conditions. The tumors were subsequently transplanted into the right axillary flanks of five mice. Following this, all mice were anesthetized by an intraperitoneal injection of 0.1 ml chloral hydrate (Shanghai Aladdin Bio-Chem Technology Co., Ltd., China), and injected with CD-PLLD containing 20 µg/g DOC and 6 µg/g MMP-9
via the tail vein. Mice were sacrificed by cervical dislocation 5, 30 or 60 min later and organs were harvested for high-performance liquid chromatography (HPLC), or 48 h later for EGFP detection.
Standard curves of DOC concentration for in vivo distribution.
Standard curves of DOC concentration in each tissue (liver, kidney, lung, heart, spleen, brain and HNE-1 tumor) were obtained by HPLC analysis. Briefly, 12.16 mg DOC standard samples were transferred into a 5 ml calibrated flask. The DOC solution was subsequently diluted with mobile phase solvent consisting of methanol and purity water (70/30, v/v) to achieve the following gradient DOC concentrations: 1,216, 608, 304, 152 and 76 µg/ml. Tissue samples harvested from nude mice bearing HNE-1 tumors were rinsed with ice-cold saline, dried on filter paper, weighed and homogenized with saline ( g: 2 ml ratio of tissue weight:saline dosage). Following this, 160 µl tissue sample and 40 µl prepared DOC standards sample solution with gradient concentration were mixed, and 1 ml tert-butyl methyl ether was added into each sample and mixed for 5 min by vortex for extraction. The total organic layer was separated by centrifugation at 11,180 x g for 10 min at 4˚C, transferred to a clean tube and evaporated to dryness at 40˚C under a stream of nitrogen. The drug residue was finally reconstituted in 0.4 ml acetonitrile followed by centrifugation at 1,1180 x g for 5 min at 4˚C prior to analysis, of which 10 µl supernatant fluid was injected into the HPLC system. The HPLC analysis of DOC was achieved on a C 18 column (Waters Corporation, Milford, MA, USA) with a mobile phase consisting of methanol and purity water (70/30, v/v) at a flow rate of 1.0 ml/min. The effluents were monitored at 227 nm and quantized by comparing the peak areas with the standard curve.
DOC distribution in vivo. Following DOC administration, nude mice bearing HNE-1 tumors were sacrificed after 5, 30 or 60 min, and the tumors and aforementioned tissues were rapidly dissected. Samples were rinsed with ice-cold saline, dried on filter paper and homogenized with saline at a 1:2 ratio of tumor weight: Saline dosage. Following this, 0.2 ml of tissue sample and 1.2 ml tert-butyl methyl ether were mixed for 5 min by vortex to extract, and the total organic layer was separated by centrifugation at 11,180 x g for 10 min at 4˚C, transferred to a clean tube, and evaporated to dryness at 40˚C under a stream of nitrogen. The drug residue was subsequently reconstituted in 0.4 ml acetonitrile and centrifuged at 11,180 x g for 5 min at 4˚C prior to analysis. The DOC concentrations were determined by HPLC analysis, which was performed using the aforementioned method.
EGFP expression in vivo. Nude mice were sacrificed by cervical dislocation after 48 h via tail vein injection of nanocomposites. HNE-1 tumor and the aforementioned tissues were immediately dissected, and EGFP expression levels in frozen sections of tumor tissue were observed via fluorescence microscope.
In vivo tumor inhibition. Nude mice implanted with HNE-1 tumors were used as the animal model to assess the efficacy of CD-PLLD/DOC/MMP-9 against tumor cells in vivo. The mice were randomly divided into four groups (n=5). Subsequently, the mice were intravenously injected via the tail vein with 250 µl saline (as control), CD-PLLD/DOC, CD-PLLD/MMP-9 or CD-PLLD/DOC/MMP-9, using DOC doses of 10 µg/g and MMP-9 doses of 3 µg/g according to the loading amount of DOC (13.20 µg/mg) and CD-PLLD/MMP-9 at the N/P ratios of 20 (16), on days 1, 6, 11 and 16, respectively. After three weeks, all mice were sacrificed by cervical dislocation. The tumor volume was calculated by the following formula: widest diameter x longest diameter 2 /2. The tumors were dissected and fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned at a thickness of 5 µm. The proliferating cell nuclear antigen (PCNA) was used to evaluate proliferation ability of the cells in the HNE-1 tumors. The PCNA expression in sections was assayed via immunohistochemistry with the Elivision two-step detection kit (Kit-0015; Fuzhou Maixin Biotech. Co., Ltd., China). These sections were deparaffinized and pretreated by boiling the slides in citrate buffer (pH 6.0) for 10 min. The sections were then immersed in 3% hydrogen peroxide for 10 min at room temperature to block endogenous tissue peroxidase activity. Following washing with phosphate buffered saline (PBS), sections were incubated with mouse PCNA monoclonal antibody (catalog no. TA800876; 1:50; Origene Technologies, Beijing, China) at 4˚C overnight, and then sections were incubated with 50 µl amplifier polymer (reagent A), and 50 µl horse radish peroxidase-conjugated anti-mouse/rabbit IgG (reagent B, Kit-0015; Fuzhou Maixin Biotech. Co., Ltd.) for 30 min at room temperature. Following washing with PBS, the sections were stained with DAB (3,3-dimethylbenzidine; Fuzhou Maixin Biotech. Co., Ltd.) and counterstained with hematoxylin (Fuzhou Maixin Biotech. Co., Ltd.), differentiated using hydrochloric acid in ethanol, blued by washing with water and sealed with conventional resin. The PCNA expression was examined with tan or brown staining in cell nucleus and no specific color in cytoplasm by light microscopy. The PCNA positive rates as positive cell index (PI) were calculated in five visual fields (x400) selected randomly in each section.
Statistical analysis. The peak area, DOC concentration and tumor size in each group were compared by two-way analysis of variance (ANOVA) and the PCNA expression of tumors in each group were compared by one-way ANOVA, followed by Tukey's post hoc test. Data was analyzed using SPSS software version 11.5 (SPSS, Inc., Chicago, IL, USA). All data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statically significant difference.
Results
In vivo metabolism assay. A linear association was determined between DOC concentration (X) and peak area (Y) in each tissue. The standard curve of DOC and regression equations were as follows: HNE-1 tumor, Y=2474.3 X + 799.96; liver, Y=2693.0 X-846.12; kidney, Y=2655.5 X + 1238.8; lung, Y=2581.3 X-172.32; heart, Y=2608.7 X-701.39; spleen, Y=2470.4 X + 266.92; and brain, Y=2755.0 X + 1459.2. Following this, tissue DOC concentrations were calculated 5, 30 and 60 min after intravenous injection with CD-PLLD/DOC/MMP-9 complexes. HPLC analysis and DOC concentration in tissues are presented in Figs. 1 and 2 , respectively. The results demonstrated that DOC was absorbed rapidly and distributed widely in the majority of tissues, and that DOC concentration was the greatest in the liver and kidney, followed by the heart, spleen and lung (P<0.05). After 60 min, DOC concentration markedly decreased, and there were no significant differences between organs (P>0.05). No DOC was detected in the brains of the nude mice. DOC concentrations in HNE-1 tumors increased with prolonged blood circulation. Following intravenous injection with CD-PLLD/DOC/MMP-9 complexes, EGFP expression after 48 h in frozen tissue sections is presented in Fig. 3 . Similar to DOC distribution, EGFP expression was detectable in all assayed organs except the brain, and the liver and kidney frozen sections exhibited greater GFP expression. EGFP expression was observed in HNE-1 tumors, consistent with the DOC concentration analysis.
In vivo tumor therapy. The antitumor effects of CD-PLLD/DOC/MMP-9 were assessed in vivo, using nude mice implanted with HNE-1 tumors. Representative tumor images are presented in Fig. 4 . Tumor volume was measured every 3 days following implantation, until mice were sacrificed at day 21 (Fig. 5 ). Tumor volume in the saline-treated control group increased greatly during this period. Treatment with CD-PLLD/DOC, CO-PLLD/MMP-9 or CD-PLLD/DOC/MMP-9 inhibited tumor growth; CD-PLLD/DOC/MMP-9 to the greatest extent (P<0.05). Inhibition of tumor volume and weight were most marked in the CD-PLLD/DOC/MMP-9-treated group compared with the control group, with reductions of 61.32 and 60.00%, respectively. Tumor volume and weight in the CD-PLLD/MMP-9-treated group were reduced 19.94 and 18.75%, respectively, and in the CD-PLLD/DOC/MMP-9-treated group were reduced 41.40 and 40.00%, respectively, compared with the control group. Tumor PCNA expression in each group is presented in Fig. 6 . Compared with the control group, PCNA expression levels in the CD-PLLD/MMP-9 group were slightly reduced, with a positive cell index (PI) of 80.62 vs. 92.83% in the control group; however, no significant differences were observed (P>0.05). PI in the CD-PLLD/DOC and CD-PLLD/DOC/MMP-9 groups were markedly reduced compared with the control group (65.36 and 39.52%, respectively), to a greater extent in the CD-PLLD/DOC/MMP-9 group (P<0.05).
Discussion
NPC is one of the most common types of malignant tumor in southern China. Currently, a combination of radiotherapy and chemotherapy is the primary clinical treatment for NPC. However, the average five-year survival rate of advanced NPC patients remains ~50% due to tumor metastasis and multi-drug resistance. The co-delivery of drugs and genes has become a primary strategy for the treatment of cancer and other diseases, due to its potential to mediate synergistic actions, improve target selectivity and inhibit the development of drug resistance (17) .
MMP-9, the enzyme with the largest molecular weight in the MMP family, may accelerate tumor invasion and metastasis due to its ability to degrade the basement membrane and extracellular matrix (18) . It has previously been revealed to mediate tumor cell proliferation and inhibit apoptosis; therefore, MMP-9 inhibition via an siRNA plasmid may be a potential therapeutic strategy (19) .
DOC, an analog of paclitaxel, is a novel anticancer agent of the taxoid family. It has been demonstrated to mediate tubulin assembly in microtubules and inhibit their depolymerization, leading to mitotic arrest in the G 2 M phase of the cell cycle (20, 21) . DOC may induce apoptosis of tumor cells and inhibit tumor growth, and has demonstrated antitumor effects in cancer chemotherapy (22, 23) . However, DOC is poorly soluble in organic solvents and water and therefore does not disperse well in plasma. Taxotere ® , the clinical formulation of DOC, is formulated in polysorbate 80, which has been identified to cause serious side-effects including hypersensitivity reactions, nephrotoxicity, cardiotoxicity and neurotoxicity (24) , limiting the clinical application of DOC. Furthermore, single-drug chemotherapy may cause additional side-effects and tumor drug-resistance. Therefore, nanocarriers that co-deliver DOC and a target gene may provide a platform to overcome these limitations.
CD is a cyclic oligosaccharide with seven glucose units bonded by a α-1, 4-linkage. It increases the water solubility of certain medicinal agents, via noncovalent inclusion complexation with a hydrophilic outer surface and a lipophilic central cavity, which encapsulates hydrophobic drug molecules or parts of these molecules. To co-deliver a chemotherapy drug and gene, our previous study prepared a biodegradable star-shaped CD-PLLD via chemical reactions with a CD surface modified with dendritic poly(L-lysine). The CD core interacted with the hydrophobic drug and the cationic arms bound to the target gene. It was demonstrated that such a conjugate may be used directly for drug and gene delivery without a complicated micellization process. In vitro assays indicated that CD-PLLD/DOC/MMP-9 complexes induce synergistic anti-tumor effects (16) .
The present study investigated the in vivo applications for NPC therapy. Using a DOC distribution analysis, compared with the liquid-liquid anhydrous diethyl ether extraction method (25) , it was demonstrated that tissue samples extracted by low-toxicity tert-butyl methyl ether are easily dried by nitrogen, acquiring an increased DOC extraction rate (26) . Due to its size, the nanomedicine is easily delivered to the tumor cell, and accumulates in tumor tissues for enhanced permeability and retention (27, 28) . Therefore, DOC concentrations in HNE-1 tumors increased with prolonged blood circulation. DOC concentrations were increased in organs rich in blood supply, including the liver and spleen, and decreased over time. GFP expression in each tissue was consistent with DOC distribution in vivo. These results indicated that CD-PLLD/DOC/MMP-9 complexes may be stable in the blood circulation. However, the complexes were easily phagocytized in reticuloendothelial systems including the liver and spleen; this requires further study. Furthermore, the complexes did not cross the blood-brain barrier due to their large molecular size, demonstrating their relative safety. Additionally, the complexes mediated increased DOC concentrations compared with prolonged blood circulation and EGFP expression in HNE-1 tumors.
In the present study, in a tumor-bearing mouse model, no significant differences were observed following treatment with CD-PLLD/MMP-9 compared with the control group. This may be due to removal of CD-PLLD/MMP-9 complexes by reticular endothelial cells in the liver and spleen, low gene concentrations in tumor, or because multiple genes are involved in tumor development, and therefore single-gene therapy is not effective. The antitumor effects were most marked in the CD-PLLD/DOC/MMP-9-treated group, as demonstrated by a clear decrease in PCNA expression levels. This may be due to the nano-characteristics of CD-PLLD, enabling it to accumulate DOC and MMP-9 in tumor tissue, and penetrate into the tumor to exert its effects in vivo (29) . PCNA is a cofactor of DNA polymerase δ, which is required for cell proliferation, and is therefore often used as an index of DNA replication and cell proliferation (30) . The present study demonstrated that tumor PCNA expression levels in CD-PLLD/DOC/MMP-9-treated mice were significantly decreased and exhibited the greatest anti-tumor effects, as demonstrated by reduced weight and volume.
In conclusion, the present study investigated the co-delivery of a hydrophobic drug and target gene. In vivo assays demonstrated that CD-PLLD/DOC/MMP-9 may inhibit HNE-1 tumor growth and decrease PCNA expression levels. These results indicated a potential novel strategy for NPC therapy.
